- Home
- RDHL vs ONCO Comparison
RDHL vs ONCO Comparison
Compare RDHL & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDHL | ONCO |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RDHL | ONCO |
|---|---|---|
| Price | $1.21 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.5K | 36.1K |
| Earning Date | 09-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,550,000.00 | $1,223,751.00 |
| Revenue This Year | $381.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 157.62 | N/A |
| 52 Week Low | $1.01 | $2.10 |
| 52 Week High | $7.44 | $179.35 |
Technical Indicators
Market Signals| Indicator | RDHL | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 40.85 |
| Support Level | $1.18 | $2.53 |
| Resistance Level | $1.26 | $3.22 |
| Average True Range (ATR) | 0.05 | 0.31 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 78.00 | 14.02 |
Price Performance
Historical ComparisonAbout RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.